Rituxan WG-MPA Patient Website
Rituxan is the first and only FDA-approved therapy for Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA), and Genentech needed a website to provide valuable information to patients. This disease is just one of multiple indications for usage of Rituxan, and the new website's creation required a simultaneous update of our interactive Rituxan main page (Rituxan.com) to provide users with a clear path to information.
In collaboration with our agency partners, we created a website that reflects patients’ experiences with Rituxan and included embedded videos and a dynamic glossary feature. The site’s clear navigation and various sidebar features keep users engaged and informed.
